Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11967669 | 1.00 | PRKCA (0.30) | PRKCA | |
| SCHEMBL527137 | 0.70 | — | — | |
| SCHEMBL4764335 | 0.69 | DYRK1A (0.44) | — | |
| SCHEMBL2679319 | 0.58 | NFKB1 (0.30) | — | |
| SCHEMBL28138488 | 0.58 | — | — | |
| SCHEMBL23966856 | 0.57 | MEN1 (0.36) | — | |
| SCHEMBL9173461 | 0.57 | — | — | |
| SCHEMBL17993974 | 0.57 | — | — | |
| SCHEMBL31526359 | 0.57 | — | — | |
| SCHEMBL183267 | 0.56 | TTK (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242168-B2 | Use of phthalide derivatives for the treatment of type 2 diabetes mellitus | DSM IP ASSETS B.V. (NL) | 2012-08-14 | — | — | US | claimed |
| US-20100298427-A1 | Anti-inflammatory compositions and their use | DSM IP ASSETS B.V. (NL) | 2010-11-25 | — | — | US | claimed |
| US-20100184852-A1 | ORGANIC COMPOUNDS FOR TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2010-07-22 | — | — | US | claimed |
| US-20090192218-A1 | USE OF PHTHALIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES MELLITUS | D ORAZIO DANIEL | 2009-07-30 | — | — | US | claimed |
| EP-1622605-B1 | USE OF PHTHALIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES MELLITUS | DSM IP ASSETS BV (NL) | 2009-07-15 | — | — | EP | claimed |
| US-20090176873-A1 | NOVEL USE OF ORGANIC COMPOUNDS | DSM IP ASSETS B.V. (NL) | 2009-07-09 | — | — | US | claimed |
| EP-1937250-A2 | LIGUSTILIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | DSMIP Assets B.V. (NL) | 2008-07-02 | — | — | EP | claimed |
| US-20070082947-A1 | Use of phthalide derivatives for the treatment and prevention of diabetes mellitus | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | US | claimed |
| WO-2006125651-A2 | LIGUSTILIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | DSM IP ASSETS B.V. (NL) | 2006-11-30 | — | — | WO | claimed |
| US-8242168-B2 | Use of phthalide derivatives for the treatment of type 2 diabetes mellitus | DSM IP ASSETS B.V. (NL) | 2012-08-14 | — | — | US | disclosed |
| US-20100298427-A1 | Anti-inflammatory compositions and their use | DSM IP ASSETS B.V. (NL) | 2010-11-25 | — | — | US | disclosed |
| US-20100184852-A1 | ORGANIC COMPOUNDS FOR TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | DSM IP ASSETS B.V. (NL) | 2010-07-22 | — | — | US | disclosed |
| US-7691420-B2 | Compositions for the treatment and prevention of diabetes mellitus | DSM IP ASSETS B.V. (NL) | 2010-04-06 | — | — | US | disclosed |
| US-20090192218-A1 | USE OF PHTHALIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES MELLITUS | D ORAZIO DANIEL | 2009-07-30 | — | — | US | disclosed |
| EP-1622605-B1 | USE OF PHTHALIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES MELLITUS | DSM IP ASSETS BV (NL) | 2009-07-15 | — | — | EP | disclosed |
| US-20090176873-A1 | NOVEL USE OF ORGANIC COMPOUNDS | DSM IP ASSETS B.V. (NL) | 2009-07-09 | — | — | US | disclosed |
| US-20070082947-A1 | Use of phthalide derivatives for the treatment and prevention of diabetes mellitus | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | US | disclosed |
| US-20070042057-A1 | Compositions for the treatment and prevention of diabetes mellitus | DSM IP ASSETS B.V. (NL) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184852-A1 | ORGANIC COMPOUNDS FOR TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION | XDH, CHRM5, CHRNA5 | PRKCA 4030/4885 |
| US-20070082947-A1 | Use of phthalide derivatives for the treatment and prevention of diabetes mellitus | IAPP, SLC5A2, SLC2A4 | PRKCA 1598/4885 |
| US-20090192218-A1 | USE OF PHTHALIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES MELLITUS | IAPP, SLC5A2, SLC2A4 | PRKCA 1598/4885 |
| US-20090176873-A1 | NOVEL USE OF ORGANIC COMPOUNDS | F12, F13B, COL1A1 | PRKCA 3591/4885 |
| US-20100298427-A1 | Anti-inflammatory compositions and their use | COL1A1, COL2A1, F12 | PRKCA 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.